Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 39S-45S

  Onderdonk, Andrew B ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG EFFECT; DRUG PENETRATION; ESCHERICHIA COLI; GROWTH INHIBITION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RAT; REVIEW; SURGICAL INFECTION;

EID: 0032450709     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00219-0     Document Type: Article

References (23)

1. Kernodle DS, Kaiser AB. Postoperative infections and antimicrobial prophylaxis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:2742-2756.
2. Nichols RL. Surgical infections: prevention and treatment -1965 to 1995. Am J Surg. 1996;172:68-74.
3. Tetteroo GWM, Wagenvoort JHT, Bruining HA. Role of selective decontamination in surgery. Br J Surg. 1992;79:300-304.
4. Anonymous. Antimicrobial prophylaxis in surgery. Med Lett. 1997;39:97-102.
5. Kernodle DS, Kaiser AB. Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection. Antimicrob Agents Chemother. 1994;38:1325-1330.
6. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36:385-394.
7. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37:955-963.
8. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(suppl B):75-80.
9. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intraabdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997;41:583-586.
10. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995;39:2210-2216.
11. Vincent J, Teng R, Dalvie DK, Friedman HL. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am J Surg. 1998;176(Suppl 6A):8S-13S.
12. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993;37:349-353.
13. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
14. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
15. Cunha BA, Hussain Qadri SM, Ueno Y, Walters EA, Domenico P. Antibacterial activity of trovafloxacin against nosocomial gram-positive and gram-negative isolates. J Antimicrob Chemother. 1997;39(suppl B):29-34.
16. Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA. Comparative in vitro activities of trovafloxacin (CP-99, 219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother. 1997;41:1146-1149.
17. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993;37:366-370.
18. Cormican MG, Jones RN. In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. J Antimicrob Chemother. 1996;37:847-849.
19. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother. 1996;40:2232-2235.
20. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38: 2471-2476.
21. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis. Infect Dis Clin Pract. 1996;5(3 suppl):S117-S119.
22. Teng R, Tensfeldt TG, Liston TE, Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr B: Biomed Appl. 1996;675:53-59.
23. Ross RA, Onderdonk AB. Activity of the antibiotic CP-99,219 (trovafloxacin) in a mixed microflora growth system model of intraabdominal infections in humans. Infect Dis Clin Pract. 1996; 5(3 suppl):S110-S112.